N/A N=50 Endoscopic Ultrasound Guided Fine Needle Biopsy (EUS-FNB-SC) Using a Novel Fork Needle
Pancreatic Cancer
Primary: Total DNA Yield of Adenocarcinoma — 5930.10; 3365.22 ng/µL — p=0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=49 Comparison of Comfilcon A Toric Contact Lenses and Samfilcon A Toric Contact Lenses
Astigmatism
Primary: Comfort at Insertion — 9.0; 8.8 units on a scale
N/A N=31 A Clinical Trial of The VisAbility Micro Insert System for Presbyopic Patients
Presbyopia
Primary: Number of Primary Eyes With Distance Corrected Near Visual Acuity (DCNVA) to 20/40 or Better and Gain of At Least 10 Letters. — 289 Participants
N/A N=409 COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel
Parkinson's Disease (PD)
Primary: Percentage of Participants on Levodopa-Carbidopa Intestinal Gel (LCIG) Monotherapy From LCIG Initiation to 12 Months — 29.3; 52.3 percentage of participants
N/A N=357 Stay Strong: A Physical Activity Program for Afghanistan and Iraq Veterans
Exercise
Primary: Change in Physical Activity (PA) as Measured by the Study-provided Monitoring Device — -67.1; -69.0 Active minutes/week
Phase 2 N=3 Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
Hematologic Malignancies · Relapse · Graft-Versus-Host Disease
Primary: Phase I: Maximum Tolerated Dose (MTD) of Carfilzomib — 36 milligrams per square meter (mg/m^2)
N/A N=240 A Trial Comparing Combined Spinal- Epidural Dosing Strategies for External Cephalic Version
Pregnancy · Pain
Primary: Success Rate of External Cephalic Version — 31; 31; 31; 30 Participants
Phase 3 N=709 An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia
Schizophrenia
Primary: Number Of Participants Reporting Severe Treatment-Emergent Adverse Events (TEAE) — 50 participants
N/A N=7,879 Education Bundle to Decrease Patient Refusal of VTE Prophylaxis
Venous Thromboembolism · Deep Venous Thrombosis · Pulmonary Embolism
Primary: Percentage of Non Administration of Prescribed VTE Prophylaxis Medication Doses — 9.1; 13.6; 5.6; 13.3 Percentage of nonadministration — p=<0.05
Phase 1 N=18 Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids
Glucocorticoids Toxicity · Glucose Intolerance
Primary: White Blood Cell Counts — 5.26; 6.99 x10^3 cells/mL
N/A N=119 MaxAn Post Market Surveillance Validation
DDD · Deformity · Tumor
Primary: Number of Participants With Differing Severity of Adjacent Level Ossification — 36; 38; 16; 10 Participants
Phase 2 N=16 Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
Leukemia
Primary: Participants With a Response CR + PR + CRi — 4; 1; 4 Participants
N/A N=20 Real-World Evaluation of the Effect of Jublia on Nail Polish
Evaluation of Jublia on Nail Polish With Healthy Toenails
Primary: Observe Stability of Nail Polish as Evidenced by Serial Photography With Efinaconazole Application in Terms of Days — 1.5; 5; 15; 5 days of stability
Phase 3 N=866 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Pancreatic Neoplasms · Digestive System Neoplasms · Neoplasms by Site
Primary: Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee — 19.4; 18.8 months — p=0.1824
Phase 2 N=42 Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
Graft Versus Host Disease · GVHD
Primary: Number of Participants Stratified by Acute Graft Versus Host Disease GVHD Stage — 6; 1 Participants